medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2011, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2011; 58 (4)

Quantitative Analysis of Torsemide in human plasma by High Performance Liquid Chromatography with ultraviolet detection

Gamboa AAB, Navoni JA, Contartese CM, Villagra AR, López CM, Villaamil LEC

Language: English
References: 27
Page: 195-200
PDF size: 61.48 Kb.


ABSTRACT

This report describes a specific and precise HPLC method for the quantification of torsemide in human plasma. The procedure included an efficient solid phase extraction, and the HPLC analysis used a phosphate buffer/acetonitrile mobile phase with a C18 column and ultraviolet detection at 288 nm. The mean absolute recovery ranged between 91.9% and 118.0%. The limit of detection was determined to be 0.010 µg/mL. The method described is suitable for torsemide plasma monitoring and pharmacokinetic studies. Data of three healthy volunteers are presented.


REFERENCES

  1. Jackson EK. Diuretics. In: Brunton LL (ed). Goodman & Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006. p. 737-769.

  2. Leikin JB, Paloucek FP. Poisoning & Toxicology Compendium. Ohio: Lexi-Comp; 1998. p. 540.

  3. Argenziano L, Morisco C, Trimarco B, Marino C, Bedoschi D, Boscani PF. Current Therapeutic Research 1998; 59: 697.

  4. Achhammer I, Häcker W et al. Arzneim Forsch Drug Res 1988; 38: 184.

  5. Physicians Desk Reference. 54th ed. Montvale, NJ: Medical Economics Company; 2000. p. 2629.

  6. Greger R. Arzneim Forsch Drug Res 1988; 38: 151.

  7. Scheen AJ. Arzneim Forsch Drug Res 1988; 38. 156.

  8. Gerh TWB, Rudy DW, Matzke GR, Kramer WG, Sica DA, Brater DC. Clin Pharmacol Ther 1994; 56: 31.

  9. Lesne M. Arzneim Forsch Drug Res 1988; 38: 160.

  10. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, Smith FE, Lane KA, Adams LD, Tierney, Brater C. Am J Med 2001; 111: 513.

  11. Noe LL, Vreeland MG, Pezzella SM, Trotter JP. Clin Therap 1999; 21: 854.

  12. Nation RL, Peng GW, Chiou WL. J Chromatogr 1979; 162: 88.

  13. Lin ET, Smith DE, Benet LZ, Hoener BA. J Chromatogr 1979; 163: 315.

  14. Rapaka RS, Roth J, Viswanathan CT, Goehl TJ, Prasad V, Cabana BE. J Chromatogr 1982; 227: 463.

  15. Kerremans ALM, Tan Y, Van Ginneken CAM, Gribnau WJ. J Chromatogr 1982; 229: 129.

  16. Jankowski A, Shorek-Jankowska A, Lamparczyk H. J Chromatogr 1997; 693: 383-391.

  17. Abou-Auda HS, Al-Yamani MJ, Morad AM, Bawazir SA, Khan SZ, Al-Khamis KI. J Chromatogr 1998; 710: 121-128.

  18. March C, Farthing D, Wells B, Besenfelder E, Karnes T. J Pharm Sci 1989; 79: 453.

  19. Quattrocchi OA, Abelaira ASI, Laba RF. En: Quattrocchi O, Abelaira S, Laba R (eds). Introducción a la HPLC. Aplicación y Práctica. Buenos Aires: 1992. p. 301.

  20. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. Eur J Drug Metab Pharmacokinet 1991; 16: 249.

  21. Olmos V, Cohen A, Villaamil EC, López CM, Roses OE. Acta Toxicol Argent 2000; 8: 13-15.

  22. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater C. Clin Pharmacol Ther 1995; 57: 601.

  23. Brater DC, Leinfelder J, Anderson SA. Clin Pharmacol Ther 1987; 42: 187-192.

  24. Gottlieb SS, Khatta M, Wentworth D, Roffman D, Fisher ML, Kramer WG. Am J Med 1998; 104: 533.

  25. Neugebauer G, Besenfelder E, Möllendorff EV. Arzneim Forsch Drug Res 1988; 38: 164.

  26. Kruck F. Arzneim Forsch Drug Res 1988; 38: 143.

  27. Broekhuysen J, Deger F, Douchamps J, Ducarne H, Herchuelz A. Eur J Clin Pharmacol 1986; 31: 29.




2020     |     www.medigraphic.com